Connective tissue disease and the lung

Clinical Pulmonary Medicine

Volumn 16, Issue 6, 2009, Pages 309-314

  Goh, Nicole S L ^a  

^a AUSTIN HEALTH   (Australia)

Author keywords

Connective tissue disease; Forced vital capacity (FVC); HRCT disease exent; Interstitial lung disease; Prognosis

Indexed keywords

AMINO ACID TRANSFER RNA LIGASE ANTIBODY; BIOLOGICAL MARKER; CREATINE KINASE; ENZYME ANTIBODY; KREBS VON DEN LUNGEN 6; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; FORCED EXPIRATORY VOLUME; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; NEUTROPHILIA; PREVALENCE; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMIC SCLEROSIS; THORAX RADIOGRAPHY;

EID: 74549226204     PISSN: 10680640     EISSN: None     Source Type: Journal    
DOI: 10.1097/CPM.0b013e3181be0eb9     Document Type: Review

References (52)

1. Bradley B, Branley HM, Egan JJ, et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax. 2008; 63(suppl 5):v1-v58.
2. D'Angelo WA, Fries JF, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med. 1969;46:428-440.
3. Owens GR, Fino GJ, Herbert DL, et al. Pulmonary function in progressive systemic sclerosis. Comparison of CREST syndrome variant with diffuse scleroderma. Chest. 1983;84:546-550.
4. Minai OA, Dweik RA, Arroliga AC. Manifestations of scleroderma pulmonary disease. Clin Chest Med. 1998;19:713-731.
5. Harrison NK, Glanville AR, Strickland B, et al. Pulmonary involvement in systemic sclerosis: the detection of early changes by thin section CT scan, bronchoalveolar lavage and 99mTc-DTPA clearance. Respir Med. 1989;83: 403-414.
6. Zrour SH, Touzi M, Bejia I, et al. Correlations between high-resolution computed tomography of the chest and clinical function in patients with rheumatoid arthritis. Prospective study in 75 patients. Joint Bone Spine. 2005;72:41-47. (Pubitemid 40169963)
7. Bilgici A, Ulusoy H, Kuru O, et al. Pulmonary involvement in rheumatoid arthritis. Rheumatol Int. 2005;25:429-435.
8. Fathi M, Dastmalchi M, Rasmussen E, et al. Interstitial lung disease, a common manifestation of newly diagnosed polymyositis and dermatomyositis. Ann Rheum Dis. 2004;63:297-301. (Pubitemid 38250674)
9. Papathanasiou MP, Constantopoulos SH, Tsampoulas C, et al. Reappraisal of respiratory abnormalities in primary and secondary Sjogren's syndrome: a controlled study. Chest. 1986;90:370-374.
10. Constantopoulos SH, Papadimitriou CS, Moutsopoulos HM. Respiratory manifestations in primary Sjogren's syndrome: a clinical, functional, and histologic study. Chest. 1985;88:226-229.
11. Kim JS, Lee KS, Koh EM, et al. Thoracic involvement of systemic lupus erythematosus: clinical, pathologic, and radiologic findings. J Comput Assist Tomogr. 2000;24:9-18.
12. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002;165:1581-1586.
13. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositisdermatomyositis- associated interstitial lung disease. Am J Respir Crit Care Med. 2001;164:1182-1185.
14. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology. 2004;44:585-596.
15. Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med. 2005;171:632-638.
16. Lee HK, Kim DS, Yoo B, et al. Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest. 2005;127: 2019-2027.
17. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175:705-711.
18. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-151.
19. Katzenstein AL, Fiorelli RF. Nonspecific interstitial pneumonia/fibrosis. Histologic features and clinical significance. Am J Surg Pathol. 1994;18:136-147.
20. Hakala M, Paakko P, Huhti E, et al. Open lung biopsy of patients with rheumatoid arthritis. Clin Rheumatol. 1990;9:452-460.
21. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This Joint Statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS Board of Directors, June 2001 and by The ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277-304.
22. Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol. 1986;10:256-267.
23. Hunninghake GW, Zimmerman MB, Schwartz DA, et al. Utility of a lung biopsy for the diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;164:193-196.
24. Swensen SJ, Aughenbaugh GL, Myers JL. Diffuse lung disease: diagnostic accuracy of CT in patients undergoing surgical biopsy of the lung. Radiology. 1997;205:229-234.
25. Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003;58: 143-148.
26. Brown KK. Rheumatoid lung disease. Proc Am Thorac Soc. 2007;4:443-448.
27. Sakaida H. IgG rheumatoid factor in rheumatoid arthritis with interstitial lung disease. Ryumachi. 1995;35:671-677.
28. Luukkainen R, Saltyshev M, Pakkasela R, et al. Relationship of rheumatoid factor to lung diffusion capacity in smoking and non-smoking patients with rheumatoid arthritis. Scand J Rheumatol. 1995;24:119-120.
29. Niewold TB, Harrison MJ, Paget SA. Anti-CCP antibody testing as a diagnostic and prognostic tool in rheumatoid arthritis. QJM. 2007;100:193-201.
30. Klareskog L, Stolt P, Lundberg K, et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006;54:38-46.
31. Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990; 77:1019-1038.
32. Schmidt WA, Wetzel W, Friedlander R, et al. Clinical and serological aspects of patients with anti-Jo-1 antibodies-an evolving spectrum of disease manifestations. Clin Rheumatol. 2000;19:371-377.
33. Nawata Y, Kurasawa K, Takabayashi K, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: prediction and treatment with cyclosporine. J Rheumatol. 1999;26:1527-1533.
34. Fudman EJ, Schnitzer TJ. Dermatomyositis without creatine kinase elevation. A poor prognostic sign. Am J Med. 1986;80:329-332.
35. Fischer A, Swigris JJ, Groshong SD, et al. Clinically significant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008;134:601-605.
36. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis. 2003;62:97-99.
37. Woodhead F, Wells AU, Desai SR. Pulmonary complications of connective tissue diseases. Clin Chest Med. 2008;29:149-164, vii.
38. Goh NS, Veeraraghavan S, Desai SR, et al. Bronchoalveolar lavage cellular profiles in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56:2005-2012.
39. Remy-Jardin M, Remy J, Cortet B, et al. Lung changes in rheumatoid arthritis: CT findings. Radiology. 1994;193:375-382.
40. Noble PW, Morris DG. Time will tell: predicting survival in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168:510-511.
41. Morgan C, Knight C, Lunt M, et al. Predictors of end stage lung disease in a cohort of patients with scleroderma. Ann Rheum Dis. 2003;62:146-150.
42. Eaton T, Young P, Milne D, et al. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171:1150-1157.
43. Buch MH, Denton CP, Furst DE, et al. Sub-maximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the six minute walk test. Ann Rheum Dis. 2007;66:169-173.
44. Wells AU, Hansell DM, Rubens MB, et al. Fibrosing alveolitis in systemic sclerosis: indices of lung function in relation to extent of disease on computed tomography. Arthritis Rheum. 1997;40:1229-1236.
45. Lynch DA, David GJ, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172:488-493.
46. Goh NS, Desai SR, Veeraraghavan S, et al. Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med. 2008;177:1248-1254.
47. Hubbard R, Venn A. The impact of coexisting connective tissue disease on survival in patients with fibrosing alveolitis. Rheumatology (Oxford). 2002; 41:676-679.
48. Witt C, Borges AC, John M, et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis: broncheoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis. 1999;58:635-640.
49. Strange C, Bolster MB, Roth MD, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008;177:91-98.
50. Wells AU, Hansell DM, Harrison NK, et al. Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis. Eur Respir J. 1993;6:797-802.
51. Yanaba K, Hasegawa M, Hamaguchi Y, et al. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis. Clin Exp Rheumatol. 2003;21:429-436.
52. Bandoh S, Fujita J, Ohtsuki Y, et al. Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/ dermatomyositis. Ann Rheum Dis. 2000;59:257-262.